MedTrace Logo

Tranexamic Acid in Proximal Humeral Fractures

NCT05437822 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-07-05

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of tranexamic acid (on blood loss and transfusion requirements in patients with proximal humeral fractures requiring open surgical approaches.

This a blinded, controlled, therapeutic trial in which the patients will be randomized to receive TXA or no drug intervention. The primary outcome is the estimated total blood loss.

This study presents only minimal risks for the included patients.

Conditions

  • Proximal Humeral Fracture
  • Surgical Treatment

Interventions

DRUG

Tranexamic acid

2 g of tranexamic acid in 50 mL of saline

Sponsors & Collaborators

  • Universidad Miguel Hernandez de Elche

    collaborator OTHER

  • Elda University Hospital

    lead OTHER

Principal Investigators

  • Alejandro Lizaur Utrilla, MD · Orthopaedic Surgery Department, Elda University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-29
Primary Completion
2023-06-21
Completion
2023-06-24

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05437822 on ClinicalTrials.gov